A Phase I, Open-Label Study to Characterise the Absorption, Distribution, Metabolism and Excretion Following a Single Oral Dose of [14C]AZD5069 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 31 May 2018
At a glance
- Drugs AZD 5069 (Primary)
- Indications Asthma; Bronchiectasis; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 May 2018 Results summarizing the PK profile of AZD5069 from eight phase 1 studies (NCT00953888, NCT01051505, NCT01083238, NCT01100047, NCT01332903, NCT01480739, NCT01735240, NCT01989520; n=240) published in the Drugs in R and D
- 06 Jul 2011 Actual end date Jul 2011 added as reported by ClinicalTrials.gov record.
- 06 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.